Y-mAbs Therapeutics reports Q2 EPS (7c), consensus (25c)

Written by Emily J. Thompson, Senior Investment Analyst

YMAB%

Updated: Aug 08 2025

0mins

Q2 Revenue Performance: The company reported a Q2 revenue of $19.5 million, exceeding the consensus estimate of $18.4 million.
Financial Outlook: This positive revenue result indicates stronger-than-expected financial performance for the quarter.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Y-mAbs Therapeutics reports Q2 EPS (7c), consensus (25c)

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

4D Molecular Therapeutics Grants 23,600 RSUs to New Employees

Tesla (TSLA) Nears Completion of AI5 Chip Design, AI6 Development Underway

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch